Create a New Forum Admin Login Member Login Contribute to Voyager Search VoyForums Help Desk VoyForums Exchange VoyForums Directory/Categories VoyForums Homepage VoyForums News FAQ - Frequently Asked Questions

[ Show ]

Support VoyForums

[ Shrink ]

VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, [2] ]

Subject: Eli Lilly Says FDA Approves Symbyax - Update [LLY] Author: Dr_stocks [ Next Thread | Previous Thread | Next Message | Previous Message ] Date Posted: 15:07:54 12/29/03 Mon Eli Lilly Says FDA Approves Symbyax - Update [LLY] 12/29/03 8:16:06 AM Monday before the bell, pharma major Eli Lilly and Co. (LLY) revealed that the FDA has approved Symbyax, which is used for the treatment of depressive episodes associated with bipolar disorder. The company noted that that Symbyax is the first FDA-approved medication for bipolar depression, and it is a combination of olanzapine, the active ingredient in Zyprexa and fluoxetine, the active ingredient in Prozac. Eli Lilly stated that Bipolar disorder is a complex mental illness characterized by debilitating mood swings ranging from episodes of deep depression marked by feelings of extreme guilt, sadness, anxiety and, at times, suicidal thoughts. The company also said that the most common adverse events reported in patients taking Symbyax in clinical trials was drowsiness, while other common events noticed were weight gain, increased appetite, feeling weak, swelling, tremor, sore throat, and difficulty concentrating. On Friday, shares of LLY ended at $70.62. [ Next Thread | Previous Thread | Next Message | Previous Message ]